KYMRKymera Therapeutics, Inc.
$110.72+83% 1Y
$110.72
$55.8052 weeks$127.24
Is the price fair?
What KYMR's price assumes
Kymera Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 87.7× revenue.
87.7
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 6.10
Price / book · today's price, trailing year to Jun 30, 2026
- EV / sales
- 79.6
EV / sales
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 6.10
- EV / EBIToperating margin −334%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 79.6
- Market capitalisation83.2 million shares, counted Jul 31, 2026
- $9.21B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
On our screens:Most shorted stocks